Acknowledgment and Consent for Disclosure of Potential Conflict(s) of Interest and Waivers under 18 U.S.C. §208(b)(3) and 21 U.S.C. §355(n)(4)

Name of Participant: Philip LaRussa, M.D.

Committee: Vaccines and Related Biological Products Advisory Committee

Meeting Date: January 25, 2007

I acknowledge that contingent upon public disclosure of the following financial interest listed below related to the review of the safety and immunogenicity of a Diphtheria and Tetanus Toxoids and Acellular Pertussis adsorbed, Inactived Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) vaccine combined (DTap-IPV-Hib), Pentacle, manufactured by Sanofi Pasteur Canada, I am eligible to receive a waiver under 21 U.S.C. §355(n)(4). My interests are exempt by the Office of Government Ethics de minimis 2640.202(a) and therefore a waiver under 18 U.S.C. §208(b)(3) is not required.

Type of Interest	Nature	Magnitude
Stock	Competing Firm	Less than $5,000
Stock	Competing Firm	Less than $5,000

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of the interests the waiver is not valid.

/s/
Philip LaRussa, M.D.

12/14/06
Date